LINK PHARMA
Medical Innovation for Bone and Cartilage
ABOUT US
Link Pharma is a leading Biotech company addressing high unmet medical needs in the field of cartilage and orthopaedics diseases.
We have a broad, diversified portfolio of disease modifying solutions in clinical development across a number of important age related orthopaedics diseases with large unmet medical needs but limited therapeutic breakthroughs.
Our major clinical focus is DMOAD, a category of disease modifying OA drugs.
Our technology is based on our proprietary approaches and know-how to access cartilage regeneration by MRI and application of biomarker to correlate with the response. BioBone is also conducting research on next generation products such as Drug-Device Combo and cell-matrix products for complicated bone defects and spinal applications.
Link Pharma是一家致力于解决骨科未满足临床需求的，技术领先的生物医药公司。
我们在骨科疾病改善型药物领域拥有丰富的研发管线，旨在为老龄化骨科疾病提供全新的治疗方式。
我们的核心竞争力在于团队具有三个技术系统的先进知识和专利，包括评价软骨结构改善的MRI方法构建系统，评价疾病进展关联程度的生物标志物系统，以及标志着新一代治疗方式的药械组合以及细胞产品等用于解决骨科复杂疾病的研发技术体系。
到2030年，美国、欧洲5国, 日本将有大约900万膝盖有资格接受BBT-01治疗
CLINICAL VALUE
OA is a flaring degenerative arthropathy and a chronic disorder which can potentially affect all synovial joints. The incidence and the disability rate of OA is high and the social burden is great.
Now there are no effective drugs to improve the joints’ structure and the clinical gap is great.
DMOAD are these drugs have an effect on the progression of the pathological changes in OA and show beneficial impact on structural progression in OA. It is proposed relative to the current symptom modifying drugs for treatment OA.
Global OA patients
> 400 million
Disability rate
53%
The market value of DMOAD
15-25 billion USD
TECHNOLOGY
USING MRI TO EVALUATE THE STRUCTURAL IMPROVEMENT
Having unique and world-leading MRI evaluation system to access cartilage regeneration, we have know how based on 100,000 cases.
INVENTIONS ON BIOMARKER FOR PARENTS GROUPING
Having proprietary approaches and know how to identify OA related biomarker and establish a system for developing orthopaedics precision medication.
KNOW HOW ON DIVERSIFIED COMBO
A range of DMOAD candidates in development and the complex orthopaedics diseases can be solved by drug-device Combo.
PIPELINE
TEAM
Management Team
Our passion for creating meaningful change for clients is what sets us apart. The Link Pharma team believes in the potential of our great idea, and it truly shows in all of our work. We work tirelessly in order to bring you a better tomorrow, and we’re proud of every single member of staff. To learn more about the incredible Link Pharma team, please have a look below.
CHRIS LADEL, PHD
Clinical
CONTACT
Netherlands